last year avisol capital partners praised the nash

Quote:

---

last year avisol capital partners praised the nash results of akero therapeutics

---

At the time they touted it the stock price was around $23 now it's $8.06.

What's very interesting is that initially Akero was pushing that it improved hepatic fat fraction and a reduction in fibrosis. A year later when they actually published in a peer review journal HFF was announced but not fibrosis. So, so many of the drugs tried for NASH reduced fat but all have failed.

https://www.fiercebiotech.com/biotech/analyst...best-class

https://www.nature.com/articles/s41591-021-01425-3#Bib1